Related Experiment Video
Updated: May 18, 2026
09:19
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
[Cost-effectiveness of a chemotherapy predictive test].
Anne-Lise Vataire1, Enora Laas, Samuel Aballéa
1Creativ-Ceutical SARL, département économie de la santé, Paris, France. ava@creativ-ceutical.com
Bulletin Du Cancer
|October 9, 2012
Summary
The Oncotype DX test for early-stage breast cancer is cost-effective in France, saving money and improving patient outcomes. This diagnostic tool helps optimize chemotherapy decisions, reducing unnecessary treatments.
Area of Science:
- Oncology
- Health Economics
- Genomics
Context:
- Adjuvant chemotherapy for early-stage breast cancer is often overused.
- The Oncotype DX test estimates 10-year recurrence risk.
- Current decision-making for chemotherapy may lead to unnecessary treatments.
Purpose:
- To evaluate the long-term cost-effectiveness of the Oncotype DX test in French clinical practice.
- To assess the impact of the test on life-years gained and quality-adjusted life-years.
- To analyze the test's role in optimizing chemotherapy prescription for ER+, HER2-, node-negative early-stage breast cancer patients.
Summary:
- A Markov model simulated the long-term effects of the Oncotype DX test in France.
- Data included international meta-analysis on test-guided treatment changes and French cost/epidemiological data.
- The analysis adhered to Haute Autorité de santé methodological recommendations.
Impact:
- The Oncotype DX test resulted in net cost savings of €570 per patient (societal perspective).
- It yielded gains of 0.15 life-years and 0.14 quality-adjusted life-years per patient.
- The test represents an efficient use of healthcare resources, optimizing chemotherapy prescription by avoiding unnecessary treatments.
Related Concept Videos
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...